Literature DB >> 29186246

Severe cutaneous adverse drug reactions of Chinese inpatients: a meta-analysis.

Qiancheng Deng1, Xia Fang1, Qinghai Zeng1, Jianyun Lu1, Chen Jing1, Jinhua Huang1.   

Abstract

BACKGROUND: The rate of severe cutaneous adverse drug reactions is low, and these reactions can result in death or disability. An evidence-based epidemiological study of severe cutaneous adverse drug reactions in China has not been reported.
OBJECTIVE: The aim of this study was to analyze epidemiology and characteristics of severe cutaneous adverse drug reactions of Chinese inpatients during the recent 15 years with meta-analysis.
METHODS: We retrospectively reviewed Chinese literature reporting severe cutaneous adverse drug reactions and collecting data from 2000 to 2015, which were in accordance with our inclusion criteria. All included data were analyzed with the Launch Open Meta-Analyst software.
RESULTS: Twenty-five articles involving 928 cases with severe cutaneous adverse drug reactions were included. Men to women ratio was 1.14:1. Twenty-one per cent of the patients had drug allergy history. Antibiotics (26.0%), sedative hypnotics and anticonvulsants (21.6%), and antipyretic analgesics (17.1%) were the most common causative drugs. The most frequent clinical subtype was Stevens-Johnson syndrome (50.1%), followed by toxic epidermal necrolysis (25.4%), exfoliative dermatitis (21.0%) and drug-induced hypersensitivity syndrome (1.6%). In addition to skin rashes, patients with severe cutaneous adverse drug reactions suffered mostly from fever (73%), and blood routine abnormality (66.7%). STUDY LIMITATIONS: This meta-analysis is limited by its retrospective design and by its methodological variation.
CONCLUSION: The most common causative drugs were antibiotics and sedative hypnotics and anticonvulsants. Stevens-Johnson syndrome was the most frequent clinical subtype of severe cutaneous adverse drug reactions. In addition to skin rashes, patients with severe cutaneous adverse drug reactions suffered mostly from fever, mucosal lesion, and hematologic abnormalities.

Entities:  

Mesh:

Year:  2017        PMID: 29186246      PMCID: PMC5514574          DOI: 10.1590/abd1806-4841.20175171

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  14 in total

1.  Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany.

Authors:  E Schöpf; A Stühmer; B Rzany; N Victor; R Zentgraf; J F Kapp
Journal:  Arch Dermatol       Date:  1991-06

2.  Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand.

Authors:  V Leenutaphong; A Sivayathorn; P Suthipinittharm; P Sunthonpalin
Journal:  Int J Dermatol       Date:  1993-06       Impact factor: 2.736

3.  [Stevens-Johnson syndrome and toxic epidermal necrolysis in Lomé (Togo). Evolutional and etiological profiles of 40 cases].

Authors:  P Pitché; C-S Padonou; K Kombate; T Mouzou; K Tchangai-Walla
Journal:  Ann Dermatol Venereol       Date:  2005 Jun-Jul       Impact factor: 0.777

Review 4.  Life-threatening acute adverse cutaneous drug reactions.

Authors:  Ronni Wolf; Edith Orion; Batsheva Marcos; Hagit Matz
Journal:  Clin Dermatol       Date:  2005 Mar-Apr       Impact factor: 3.541

5.  Epidemiological study of severe cutaneous adverse drug reactions in a city district of China.

Authors:  L-F Li; C Ma
Journal:  Clin Exp Dermatol       Date:  2006-09       Impact factor: 3.470

6.  Severe adverse cutaneous drug eruptions: epidemiological and clinical features.

Authors:  Inès Zaraa; Meriem Jones; Sondes Trojjet; Rym Cheikh Rouhou; Dalenda El Euch; Mourad Mokni; Amel Ben Osman
Journal:  Int J Dermatol       Date:  2011-07       Impact factor: 2.736

7.  Cutaneous adverse drug reactions in hospitalised patients.

Authors:  H Y Lee; L K Tay; T Thirumoorthy; S M Pang
Journal:  Singapore Med J       Date:  2010-10       Impact factor: 1.858

Review 8.  Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome.

Authors:  Pierre-Dominique Ghislain; Jean-Claude Roujeau
Journal:  Dermatol Online J       Date:  2002-06

9.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Authors:  J C Roujeau; J P Kelly; L Naldi; B Rzany; R S Stern; T Anderson; A Auquier; S Bastuji-Garin; O Correia; F Locati
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

10.  Severe cutaneous adverse reactions in a local hospital setting: a 5-year retrospective study.

Authors:  Peiqi Su; Chen Wee Derrick Aw
Journal:  Int J Dermatol       Date:  2014-07-29       Impact factor: 2.736

View more
  4 in total

1.  Evolution of HLA-B Pharmacogenomics and the Importance of PGx Data Integration in Health Care System: A 10 Years Retrospective Study in Thailand.

Authors:  Napatrupron Koomdee; Chiraphat Kloypan; Pimonpan Jinda; Jiratha Rachanakul; Thawinee Jantararoungtong; Rattanaporn Sukprasong; Santirhat Prommas; Nutthan Nuntharadthanaphong; Apichaya Puangpetch; Maliheh Ershadian; Shobana John; Mohitosh Biswas; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2022-04-05       Impact factor: 5.988

2.  Epidemiology of Severe Cutaneous Adverse Drug Reaction and Its HLA Association among Pediatrics.

Authors:  Hossein Esmaeilzadeh; Shirin Farjadian; Soheila Alyasin; Hamid Nemati; Hesamodin Nabavizadeh; Elmira Esmaeilzadeh
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

3.  Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017.

Authors:  Hyun Kyung Kim; Dae Yeon Kim; Eun Kee Bae; Dong Wook Kim
Journal:  J Korean Med Sci       Date:  2020-02-03       Impact factor: 2.153

4.  Clinical aspects and therapeutic approach of drug-induced adverse skin reactions in a quaternary hospital: a retrospective study with 219 cases.

Authors:  Júlia Chain Martins; Camila Arai Seque; Adriana Maria Porro
Journal:  An Bras Dermatol       Date:  2022-04-02       Impact factor: 2.113

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.